



Filing of Form 10-Q for Second Quarter

August 11, 2022

RNS Number : 6259V

MaxCyte, Inc.

11 August 2022



MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022

ROCKVILLE, MD, August 11, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.

A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, <https://investors.maxcyte.com/>.

MaxCyte Contacts:

US IR Adviser

+1 415-937-5400

Gilmartin Group

ir@maxcyte.com

David Deuchler, CFA

US Media Relations

+1 408-497-8568

Seismic

Valerie Enes

Nominated Adviser and

+44 (0)20 7886 2500

Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

UK IR Adviser

Consilium Strategic

+44 (0)203 709 5700

Communications

Mary-Jane Elliott

Chris Welsh

maxcyte@consilium-

comms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCURVNRURUWAAR